Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Articolo
Data di Pubblicazione:
2011
Citazione:
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial / Viale G, 1.7.7., Regan, M.m., Dell’Orto, P., Mastropasqua, M.g., Maiorano, E., Rasmussen, B.b., Macgrogan, G., Forbes, J.f., Paridaens, R.j., Colleoni, M., Làng, I., Thurlimann, ., Mouridsen, H., Mauriac, L., Gelber, R.d., Price, K.n., Goldhirsch, A., Gusterson, B.a., Coates, A.s.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 22:10(2011), pp. 2201-2207. [10.1093/annonc/mdq738]
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Breast cancer; Therapy; clinical trial
Elenco autori:
Viale G, 1. 7. 7.; Regan, Mm; Dell’Orto, P; Mastropasqua, Mg; Maiorano, Eugenio; Rasmussen, Bb; Macgrogan, G; Forbes, Jf; Paridaens, Rj; Colleoni, M; Làng, I; Thurlimann, ; Mouridsen, H; Mauriac, L; Gelber, Rd; Price, Kn; Goldhirsch, A; Gusterson, Ba; Coates, As
Link alla scheda completa:
Pubblicato in: